Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06047886 · ClinicalTrials.gov registry record · Phase 1

UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

A Phase 1 study of Myelodysplastic Syndromes and Primary Myelofibrosis, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
Phase 1
Development phase
50
Enrollment target
1
Study location

NCT06047886 is a Phase 1 study of Myelodysplastic Syndromes and Primary Myelofibrosis that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 50 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06047886, a Phase 1 study of Myelodysplastic Syndromes and Primary Myelofibrosis, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
Phase 1
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

Patients with graft failure or delayed engraftment may benefit from a hematopoietic stem cell boost or an additional hematopoietic stem cell transplantation procedure. In such settings standard immune suppression strategies are avoided due to their myelosuppressive nature. Therefore those patients are at increased risk of graft versus host disease, and the infusion of a CD34 selected graft would reduce such a risk. The infusion of CD34 selected graft using CliniMACS plus is currently FDA FDA-approved indication for acute myeloid leukemia. However, the use of the Prodigy would streamline the processing, in terms of hands-off procedure, allowing to provision of this product to the patients without strains on the cell therapy lab team. This procedure has been demonstrated safe and effective in several single-center studies and is currently in advanced phase investigation in several studies for malignant and non-malignant conditions.

Conditions Studied

Myelodysplastic Syndromes Primary Myelofibrosis AML ALL CML Lymphoid Malignancies

Interventions

  • DRUG Infusion of CD34 selected hematopoietic stem cells

Study Locations (1)

Alabama

  • University of Alabama at Birmingham - Birmingham

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-04-22
Est. Completion 2029-12
Phase Phase 1

Sponsor

University of Alabama at Birmingham

1,160 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06047886

The ClinicalTrials.gov registry entry for NCT06047886 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (82% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which Infusion of CD34 selected hematopoietic stem cells is the first listed.

NCT06047886 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.

Frequently Asked Questions

What is clinical trial NCT06047886 about?

NCT06047886 is a clinical study titled "UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy". Patients with graft failure or delayed engraftment may benefit from a hematopoietic stem cell boost or an additional hematopoietic stem cell transplantation procedure. In such settings standard immune suppression strategies are avoided due to their myelosuppressive nature. Therefore those patients a...

What is the current status of trial NCT06047886?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2025-04-22. Estimated completion is 2029-12.

What conditions does trial NCT06047886 study?

This clinical trial studies the following conditions: Myelodysplastic Syndromes, Primary Myelofibrosis, AML, ALL, CML.

What interventions are being tested in trial NCT06047886?

The interventions under investigation include: Infusion of CD34 selected hematopoietic stem cells (DRUG).

Who is sponsoring clinical trial NCT06047886?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06047886 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myelodysplastic Syndromes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myelodysplastic Syndromes

All registered trials for this condition

Primary Myelofibrosis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.